As chair of the candidate's graduate committee, I have read the project of Amanda Gloria Lewis in its final form and have found that (1) its format, citations, and bibliographical style are consistent and acceptable and fulfill university and college style requirements; (2) its illustrative materials including figures, tables, and charts are in place; and (3) the final manuscript is satisfactory to the graduate committee and is ready for submission to the university library. Results: Ten studies reported long-chain ω-3 fatty acids to be effective in the treatment of hypertriglyceridemia. The average decrease in triglycerides (TG) was 29%, total cholesterol (T C ) 11.6%, very low density lipoprotein (VLDL) 30.2%, and low-density lipoprotein (LDL) 32.5%. One study found LDLs to increase by 25%. The average increase in high-density lipoprotein (HDL) was 10%. The overall average MQI score was Treatment of Hypertriglyceridemia 36% (26%-54%). Many of the RCTs had serious shortcomings including short duration, lack of a power analysis, no intention to treat analysis, no report of blind assessment of outcome, and lack of dietary control as a confounding variable.
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List of Tables   Table 1. and low-density lipoprotein (LDL) levels, while a high level of high-density lipoprotein (HDL) has been shown to be cardioprotective. High levels of triglycerides (TG) have recently been reported as a risk factor for CHD independent of the HDL level (Fruchart & Duriez, 2002; Gotto, 2002) .
Women typically have lower T C levels than men until they reach menopause.
After menopause T C levels begin to climb until the levels actually exceed those of men (National Health and Nutrition Examination Surveys, 2002) . Recent evidence suggests that the relative risk of cardiovascular disease for women with hypertriglyceridemia is higher than for men (RR = 1.75 vs. 1.30). Even after accounting for HDL levels, men and women with elevated TG have a significantly higher risk for CHD (Austin, 1998) .
The combination of high TG and low HDL levels associated with insulin resistance contribute substantially to CHD. The cluster of symptoms identified as insulin resistance includes borderline high blood glucose levels, hypertension, increased uric acid levels, and central obesity. If individuals with insulin resistance have a T C level considered borderline by the National Cholesterol Education Program Adult Treatment Panel III guidelines, they are not categorized as being at higher risk for CHD (Fruchart & Duriez, 2002) .
The goals of hyperlipidemia management remain primary and secondary prevention of CHD. Current treatment includes diets low in saturated fat and cholesterol, exercise, and medications such as statins, niacin, cholesterol absorption inhibitors, bile acid sequestrants, and a derivative of fibric acid (gemfibrozil). Beginning in the late 1970s, preliminary research suggested that long chain omega-3 (ω-3) fatty acids prevented CHD. The two long chain ω-3 fatty acids that are thought to have cardioprotective effects are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Unlike ω-6 fatty acids, EPA and DHA lower postprandial lipemia and prevent the lowering of HDL. EPA also lowers T C and TG levels by preventing LDL and TG synthesis in the liver (Harper & Jacobson, 2001 ).
Several randomized controlled trials (RCTs) and observational studies reported a decline in TG levels when long chain ω-3 fatty acids were consumed (Harper & Jacobson, 2001 ). However, questions remain regarding their use to treat mild to moderate hypertriglyceridemia. Much of the debate centers on the effectiveness of ω-3 fatty acid supplements as opposed to dietary intake of ω-3 fatty acids and the recommended dose of the supplement. Therefore, the purposes of this systematic review are to evaluate the evidence available on long chain ω-3 fatty acids in secondary prevention of hypertriglyceridemia in otherwise healthy individuals, determine the best treatment options, and make recommendations for clinical practice.
Methods

Identification of Studies
An electronic search was conducted to identify studies from January 1994 to February 2003 in the following databases: EMBASE, MANTIS, Biosis Previews, Science Search, International Pharmaceutical Abstracts, MEDLINE, PubMed, CINAHL, and the Cochrane Library. The search terms used were: eicosapentaenoic acid, EPA, Treatment of Hypertriglyceridemia 3 docosahexaenoic acid, DHA, ω-3 fatty acids, adult, human, randomized controlled trial, hyperlipidemia, and hypertriglyceridemia. The search was limited to studies published in English. Reference lists of identified articles were searched for additional studies that had been missed. Nine randomized controlled trials were found that matched the search criteria. Contact persons for each of the identified studies were sent a complete list of studies via letter or email and were asked to identify any studies not yet published or not included in the list. One month was allowed for a response. Six of the contacts did not respond to the request. One additional study was identified through contact correspondence (Mori et al., 2000) . A list of excluded articles is available from the authors by request.
Inclusion/Exclusion Criteria
For inclusion in the review study subjects must have had TG levels greater than 150 mg/dL and/or T C greater than 200 mg/dL. Studies were included if the ω-3 fatty acids EPA and/or DHA were ingested in doses greater than or equal to 3 g/d. All types of hyperlipidemia were included in this review because, in most instances, subjects were not classified by type. Studies were excluded if the subjects had secondary hypertriglyceridemia, known CHD including hypertension, a strong family history of CHD, were part of an ethnic population associated with higher incidences of CHD, had diabetes mellitus or fasting blood sugar levels greater than 130 mg/dL, hypothyroidism, were smokers, alcohol abusers, used hormone replacement therapy for control of menopausal symptoms, or used statins or gemfibrozil as treatment options.
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Data Extraction
The Boyack and Lookinland Methodological Quality Index (MQI) (Boyack, Lookinland, & Chasson, 2002) was used to evaluate the quality of the studies included in the review (Table 1 ). The tool evaluates the strength of the study's design, methods, and analysis. Each study was scored by two independent reviewers (A. L., and S. L.), differences were settled, and consensus was reached by referring to the original study.
Overall inter-rater reliability was r = 0.92. In order to score an article, the information provided in the study was compared with the MQI tool and each item was scored. The final score for an individual study was presented as a percentage. The percentage was found by taking the study's total score and dividing it by the total possible score. 
Results
Study Characteristics
A total of 10 RCTs were identified from the medical and nutritional literature.
Three of the 10 studies involved multiple sites (Borthwick, 1998; Harris et al., 1997; Mackness et al, 1994) . Although one study was conducted in the United States, most research on ω-3 fatty acids took place in other countries (Australia, Canada, Italy, Norway, Portugal, and the United Kingdom). All of the study designs were RCTs with one using a crossover trial (Calabresi, Donati, Pazzucconi, Sirtori, & Franceschini, 2000) .
The length of the studies ranged from 4 to 16 weeks.
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A weakness in all of the studies was a lack of a power analysis. None had a duration longer than 16 weeks, making it difficult to determine the effectiveness of longterm treatment. None of the studies were long enough to be able to report the long-term health outcomes of acute cardiac event prevention, but rather focused on surrogate lipid measures.
Although all the studies reported a decrease in TG, none controlled for diet which could be a major confounding variable if participants in the studies consumed large amounts of ω-3 fatty acids in their diet. Only one of the studies had their participants follow the National Cholesterol Education Program Step I diet while monitoring compliance (Harris et al., 1997) .
Quality of Studies
Each study received a quality score from the Boyack and Lookinland MQI that ranged from 26% to 54% out of a possible 100% ( Table 2 ). The average total MQI for the 10 studies was 36%. The higher the score the more closely it matched the standards of the quality index and the higher its methodological soundness. No minimum score was necessary to be included in this review.
Patient Characteristics
A total of 606 people were studied overall with 83 % being male (n = 505).
Sample sizes ranged from 14 to 234 with no ethnic minorities included. In the majority of cases the type of hyperlipidemia was not identified. There are seven basic types of hyperlipidemia (Table 3) , including types I through V, secondary hypertriglyceridemia, and familial lecithin cholesterol acyltransferase deficiency (Beers & Berkow, 1999) .
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Treatment Characteristics
Pronova Biocare (Oslo, Norway), the manufacturer of Omacor and K-85, provided funding for five of the six studies that used their products. Other ω-3 preparations included those from Croda Chemicals (Laidlaw & Holub, 2003) , Fish Oil Test Materials Program (Mori et al., 2000) , and Hebron (Silva et al., 1996) . Dosages of ω-3 fatty acids ranged from 3.4 -4 g per day either as combinations of DHA and EPA or DHA and EPA separately. One study examined the effects of DHA and EPA and varying doses of gamma-linolenic acid (Laidlaw & Holub, 2003) . Another study used a crossover design with Omacor and thus had no placebo (Calabresi et al., 2000) . The placebos used in the remaining studies were corn oil (6), soya oil (1), and olive oil (1).
Clinical Outcomes
All studies except Silva et al. (1996) reported significant decreases in TG levels when study participants were treated with ω-3 fatty acids in dosages of greater than 3.4 g per day. However, participants included in Silva et al. were consuming fish meals more than six times per week and thus had a significant dietary source of ω-3 fatty acids. The average decrease in TG levels in the studies that found a significant change was 29% (range = 16%-45%). In the three studies that looked at T C the average decrease was 9.3% (Grimsgaard, Bønaa, Hansen, & Nordøy, 1997; Harris et al., 1997; Laidlaw & Holub, 2003) . However, seven studies found that EPA and DHA had no significant effect on T C levels (Borthwick, 1998; Chan et al., 2003; Goodfellow, Bellamy, Ramsey, Jones, & Lewis, 2000; Laidlaw & Holub; Mackness et al., 1994; Mori et al., 2002; Silva et al.) .
LDL decreased 11.3% in one study (Laidlaw & Holub) . However, three studies found LDL to increase significantly (Calabresi et al., 2000; Harris et al.; Mori et al.) by an Treatment of Hypertriglyceridemia 7 average of 21.6% (range = 8%-32%), while others found no significant change in LDL ( 
Discussion
Although all of the studies found a significant decrease in TG, the average quality index score of 36% indicates that the studies were of relatively low quality. However, the average overall score to determine the effectiveness of ω-3 fatty acids in this review is comparable to the MQI score recently reported in a study examining the effectiveness of using garlic to treat elevated lipid levels (Alder, Lookinland, Berry, & Williams, 2003) .
Many of the same methodological flaws reported by Alder et al., were seen here as well.
These included small sample sizes, a lack of a power analysis, and a lack of control for confounding variables such as fish intake. Additionally, all of the studies were of such a short duration (range 4-16 weeks) that it was impossible to evaluate the effectiveness of long-term ω-3 fatty acid supplementation on hypertension and CHD prevention.
However, Harris (1996) reported that continued supplementation with ω-3 fatty acids resulted in lowering TG even after 7 years of treatment.
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Studies would have received higher MQI scores if more information on treatment concealment and on blind assessment of outcomes was provided and limitations and biases were reported. None of the studies did a power analysis before undertaking the study. Without a power analysis it would be difficult to determine if negative findings were truly negative or whether a type II error was made. Biases can occur without concealment of treatment since the researchers may know the study groups to which participants were assigned. These risk calculators could be used to guide the practitioner in identifying patients who are at an increased risk of developing CHD in order to institute preventative therapies.
None of the studies addressed possible confounding variables by controlling for diet during the study. A diet low in saturated fats and high in ω-3 fatty acids is the first step in the treatment of patients with increased lipid levels (National Cholesterol Panel, 2002) . While it is very costly to strictly control diet during the course of a study, it is impossible to isolate the efficacy of ω-3 fatty acids if subjects are consuming significant amounts of dietary ω-3 fatty acids. It is important to mention that when testing the effectiveness of ω-3 fatty acids in real life clinical situations, the practitioner has no control over an individual patient's diet. When analyzing future studies evaluating the efficacy of ω-3 fatty acids, the reader must evaluate the extent of dietary control, power analysis, intention to treat analysis, and reporting of biases and flaws in the study.
Although the underlying mechanism of action of ω-3 fatty acids remains unknown, studies have shown that their effects are dose related (Carroll & Roth, 2002; Sanders, 1991) . Chan et al. (2003) postulated that ω-3 fatty acids reduce TG by lowering the production of VLDL apolipoprotein B, thus decreasing cholesterol synthesis in the liver. The decreased synthesis of VLDL results in a lower level in the blood and more VLDL converted into LDL. Others (Calabresi et al., 2000) believe that ω-3 fatty acids decrease TG by altering lipoprotein metabolism in the liver and exerting an effect on target lipid genes. When synthesis of TG and VLDL is decreased, the breakdown of intermediate-density lipoprotein (IDL) is also decreased and more IDL particles are converted to LDL. However, since LDL particles are not broken down this may result in a rise in LDL. In patients with type IV and V hyperlipidemias LDL increased as TG decreased with ω-3 fatty acid supplementation (Calabresi et al., 2000; Sanders, 1991) .
Large lipid particles, such as chylomicrons and VLDL, cannot pass through the endothelial wall and are deposited in the blood vessel intima. Because small particles such as small VLDL particles, VLDL remnants, and IDLs, can easily pass through the Treatment of Hypertriglyceridemia 10 endothelial barrier they are considered highly atherogenic (Fruchart & Duriez, 2002) . It is known that small VLDL particles are easily converted to LDL (Sanders, 1991) .
Although TG can be lowered by dietary intake of long chain ω-3 fatty acids, the amount needed to achieve therapeutic levels depends on the type of fish consumed (Table   4) . Although there are other non-fish sources of ω-3 fatty acids, studies have not confirmed the benefits of non-fish oil sources. In the typical American diet the total intake of ω-3 fatty acids is ≈ 1. The amount of fish needed to lower TG levels can be difficult to consume because of the high cost of fish, the risk of environmental toxins with certain species of fish, and the vast amounts needed to achieve a decrease in TG levels. Omega-3 fatty acid supplements are considered a food supplement by the Food and Drug Administration, and different preparations contain varying amounts of DHA and EPA. The most common ω-3 fatty acid supplements contain 180 mg of EPA and 120 mg of DHA in each capsule The efficacy of ω-3 fatty acid supplementation also depends heavily on the type of hyperlipidemia being treated. For those with type II or III hyperlipoproteinemia, fish oil supplements will slightly decrease TG and VLDL, and have no effect on LDL or T C levels. In those with type IV or V, however, a significant decrease in TG will result in a rise in LDL and little or no change in T C with possible slight or no increases in HDL (Sanders, 1991) .
Omega-6 fatty acids are the fatty acids consumed in largest amounts by most Americans. Some of the common sources of ω-6 fatty acids are walnuts, brazil nuts, canola, corn, evening primrose, sesame, safflower, soya, and sunflower oil (Willett, 2001 ). They reduce T C , decrease cholesterol deposits in vessels, and cause a slight decrease in TG levels (Kris-Etherton, 1999). Although the majority of studies reviewed used an ω-6 fatty acid as placebo, this was not considered a methodological flaw since this is the major dietary source of fatty acids in the United States.
Other benefits have been associated with the intake of ω-3 fatty acids. A strong negative relationship has been found between fish intake or supplementation and risk of sudden death (Albert et al., 1998; Siscovick et al., 1995) and coronary heart disease (Djousse et al., 2001 ). These findings have been confirmed in healthy men as well (Albert et al., 2002) . A lower risk (RR = 0.4) of acute myocardial infarction (AMI) was reported in both sexes (Landmark et al., 1998) . In those who suffered an AMI, the infarct size was smaller (Guallar et al., 1999) .
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While the current evidence suggests that supplementation of ω-3 fatty acids in doses greater than 3.4 g in Caucasian males with hypertriglyceridemia results in a decrease in TG, there are still important questions that need to be answered before practitioners can safely recommend them to their patients. Future large RCTs need to focus on ω-3 fatty acid supplementation in approximate doses of 4 g/d in women and minorities with high TG levels since insufficient evidence exists to support practice recommendations in these groups. Future studies should stratify by types of hyperlipidemia to control for LDL and T C since ω-3 fatty acids have differential effects based on the hyperlipidemia classification.
Conclusion
All of the recent studies (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) that evaluated the effect of long-chain ω-3 fatty acids on hypertriglyceridemia have methodological flaws. None performed a power analysis before recruiting participants, which resulted in underpowered studies. There was no control for confounding variables such as dietary intake of ω-3 fatty acids, no report on double blind assessment of outcomes, and no intention to treat analysis. The absence of these critical elements made it difficult to draw a conclusion about the efficacy of the use of long-chain ω-3 fatty acids in the treatment of hypertriglyceridemia.
The Consolidated Standards of Reporting Trials (CONSORT) guidelines should be followed as future studies are developed to improve study reporting (Moher, Schulz, & Altman, 2001) . Although the evidence supporting the use of long-chain ω-3 fatty acids in the secondary prevention of hypertriglyceridemia is fairly strong, until there are larger RCTs with longer durations the authors cannot recommend the use of long-chain ω-3 Treatment of Hypertriglyceridemia 13 fatty acids in the treatment of secondary hypertriglyceridemia in lieu of lipid lowering medications. DM = diabetes mellitus; CVD = cardiovascular disease; BMI = body mass index; TG = triglycerides; T C = total cholesterol; LDL = total low-density lipoprotein; VLDL = total very-low-density lipoprotein; HDL = total high-density lipoprotein; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; GLA = gamma-linolenic acid; Lp(a) = lipoprotein a; FCHL = Familial combine hyperlipidemia; HRT = hormone replacement therapy; HTN = hypertension; PV = peripheral vascular, ALT = alanine aminotransferase; MI = myocardial infarction 
